Mortality rates among United States veterans with sarcoidosis have been rising since 2004, most notably in men, according to ...

Among those treated for sarcoidosis in the year following diagnosis, 60% used steroids alone, 13% nonsteroidal immunosuppressives alone, and 27% received both. About 43% of patients with sarcoidosis ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

While some patients with sarcoidosis have spontaneous disease remission, others may require treatment for symptom management, organ involvement, and/or risk reduction of disease progression.

Sarcoidosis is a multi-systemic disease of unknown etiology with a ... This work was a product of the annual Pulmonary and Critical Care Research Fellows Crash Course supported by Boston ...

These can cluster in the organs of the body, typically the lungs and lymph nodes ... around 1.2 million live with the disease worldwide. For many people with sarcoidosis, symptoms often improve ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Using skin, lung, and blood samples from sarcoidosis ... Gross Professor of Dermatology and the director of Penn's Cutaneous ...

autoimmune-related advanced lung disease, sarcoidosis, and silicosis. We also provide our patients access to educational material and teaching sessions, including classes and supportive face-to-face ...

The most common diseases for lung transplant referral are interstitial lung diseases including pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary hypertension, cystic fibrosis, ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.